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Behcet’s Disease (BD) is a multisystem inflammatory disor-
der of chronic course, highly frequent in certain ethnic
groups (Turks, Israelis, Oriental). Although the disease is
considered of low prevalence in children, recent registries
indicates an increase in disease recognition. It characterizes
by a broad spectrum of clinical manifestations, including
ocular, musculoskeletal, CNS, gastrointestinal, vascular and
mucocutaneous involvement. Its pathogenesis is very com-
plex to be classified exclusively as an autoimmune or auto-
inflammatory entity. Objective: To describe the clinical and
therapeutical characteristics of a series of patients with BD
of onset in childhood. Patients and Methods: We reviewed
the clinical charts of patients with BD age of onset ≤ 16
years, evaluated in our Rheumatology Section since 1994.
The disease diagnosis was based on the International Study
Group (ISG) criteria. Different variables were analyzed:
demographic (including ancestry, age at presentation and
delay time to diagnosis), clinical symptoms and affected
organs, laboratory and therapeutic management (corticos-
teroids, immunosuppressive and biological agents) consid-
ering the response achieved. Results: 6 patients with BD
were included, 4 females (66.7%) with mean age at onset of
symptoms 9.05 years (range 4-12) and mean age at diagno-
sis 12.2 years (r 9-16). The average time of delay in diag-
nosis was 3.12 years. Turkish, Israeli and Armenian
ancestry was found in 4 patients. No patient had positive
family history of BD. Half of pts met criteria for classifica-
tion of ISG. All patients had recurrent oral ulcers and
66.6% genital ulcers (n = 4) with no gender prevalence.
Cutaneous manifestations were observed in 4 patients
(66.6%) and consisted in erythema nodosum. The pathergy
test was performed on 2 patients being negative. Four chil-
dren presented uveitis (2 with hypopyon), and 2 of them
received Infliximab as treatment due to a severe course
(visual acuity 1/10). Clinical onset related to gastrointest-
inal symptoms (abdominal pain and enterorrhagia) was
observed in 2 girls, associate in one case with neurological
manifestations (pseudotumor cerebri). Molecular analysis
was performed only in 1patient being HLA-B51 positive.
All patients received steroids. Conclusion: In our series of
patients with BD, the prevalence of clinical manifestations
was similar to other series. Suspected symptoms of BD in
the pediatric group are crucial for an early diagnosis and
appropriate treatment.
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Table 1
Pt Age Dx / Gender Oral/genital Ulcers Compromised systems Treatments Response
1 16 / M +/+ Eyes, skin, epididimitis Methotrexate, Cyclosporine, Infliximab Partial
2 12/F +/+ Skin, CNS Azathioprine, Mesalazine, Thalidomide Complete
3 9/F + / + Skin, eyes, Gastrointestinal Azathioprine Complete
4 10/F + / - Eyes Azathioprine, Infliximab Partial
5 14/M + / + Skin, eyes, arthritis Colchicine, MTX, Azathioprine Complete
6 12/F + / - Eyes Cyclosporine, Azathioprin Complete
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